Jump to content

PSI-6130: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
BogBot (talk | contribs)
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikiped
Line 2: Line 2:


{{Drugbox
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 444038782
| verifiedrevid = 444040364
| IUPAC_name = 4-Amino-1-((2''R'',3''R'',4''R'',5''R'')-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1''H'')-one
| IUPAC_name = 4-Amino-1-((2''R'',3''R'',4''R'',5''R'')-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1''H'')-one
| image = PSI-6130.png
| image = PSI-6130.png

Revision as of 20:41, 20 September 2011

PSI-6130
Clinical data
ATC code
  • none
Identifiers
  • 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
CAS Number
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H14FN3O4
Molar mass259.23 g/mol g·mol−1
  (verify)

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark.[1] Specifically, PSI-6130 inhibits the hepatitis C virus NS5B RNA dependant RNA polymerase.[2]

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.[4][unreliable source?]

References

  1. ^ Clark, J.; et al. (2005). "Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504. doi:10.1021/jm0502788. PMID 16107149. {{cite journal}}: Explicit use of et al. in: |author= (help)
  2. ^ Lieven J Stuyver, Tamara R McBrayer, Phillip M Tharnish, Jeremy Clark, Laurent Hollecker; et al. (2006). "Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication". Antiviral Chemistry & Chemotherapy. 17 (2): 79–87. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  3. ^ Cole, P.; Castaner, R.; Bolos, J. (2009). "R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection". Drugs of the Future. 34 (4): 282–290.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ "INFORM-1 (R7227 and R7128) study".